State-of-the-Art Treatment on Chemotherapy and Immunotherapy for Urological Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 2635
Special Issue Editors
Interests: prostate cancer; androgen receptor; castration-resistant prostate cancer; immuno-oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The recent progress of medical oncology in urological cancer is remarkable. Immune checkpoint inhibitors, antibody–drug conjugates, and molecular targeting agents for kidney and urothelial cancer have dramatically changed the treatment system and philosophy. Radioligand therapy for prostate cancer is a promising modality and is now used worldwide. Although these novel concepts of treatment strategies contribute to the improvement of patient’s survival and quality of life, most patients with advanced cancer still cannot be cured, and the cancer cells at metastatic sites are hardly eradicated. In addition, urological rare cancers such as urachal cancer, penile cancer, adrenal cancer, and retroperitoneal sarcoma still have no standard therapy. This Special Issue calls for clinical studies and reviews of state-of-the-art treatments for urological cancers. Basic research dissecting biological, pathological, and pharmacological mechanisms for the development of novel treatments in urological cancers is also welcome.
Prof. Dr. Kouji Izumi
Dr. Hiroshi Yaegashi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chemotherapy
- immunotherapy
- antibody–drug conjugate
- radioligand therapy
- urological cancer
- prostate cancer
- kidney cancer
- urothelial cancer
- urachal cancer
- penile cancer
- adrenal cancer
- sarcoma
- clinical trial
- basic research
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
